206 related articles for article (PubMed ID: 26718955)
1. Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2016 Apr; 33(4):1003-17. PubMed ID: 26718955
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2014 Oct; 31(10):2605-17. PubMed ID: 24792824
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
5. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D
Vanover KE; Davis RE; Zhou Y; Ye W; Brašić JR; Gapasin L; Saillard J; Weingart M; Litman RE; Mates S; Wong DF
Neuropsychopharmacology; 2019 Feb; 44(3):598-605. PubMed ID: 30449883
[TBL] [Abstract][Full Text] [Related]
7. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
9. Prediction of CNS occupancy of dopamine D2 receptor based on systemic exposure and in vitro experiments.
Kanamitsu K; Arakawa R; Sugiyama Y; Suhara T; Kusuhara H
Drug Metab Pharmacokinet; 2016 Dec; 31(6):395-404. PubMed ID: 27745731
[TBL] [Abstract][Full Text] [Related]
10. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2011 Oct; 28(10):2490-504. PubMed ID: 21647790
[TBL] [Abstract][Full Text] [Related]
12. A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.
Eugene AR; Masiak J
Nord J Psychiatry; 2017 Aug; 71(6):417-424. PubMed ID: 28486094
[TBL] [Abstract][Full Text] [Related]
13. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
14. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study.
Corripio I; Ferreira A; Portella MJ; Pérez V; Escartí MJ; Del Valle Camacho M; Sauras RB; Alonso A; Grasa EM; Carrió I; Catafau AM; Alvarez E
Psychiatry Res; 2012 Jan; 201(1):73-7. PubMed ID: 22281201
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High).
Seeman P
Schizophr Res; 2009 Apr; 109(1-3):191-2. PubMed ID: 19171464
[No Abstract] [Full Text] [Related]
16. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
17. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
McCormick PN; Wilson VS; Wilson AA; Remington GJ
Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779
[TBL] [Abstract][Full Text] [Related]
18. Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study.
Lim HS; Kim SJ; Noh YH; Lee BC; Jin SJ; Park HS; Kim S; Jang IJ; Kim SE
Pharm Res; 2013 Mar; 30(3):683-93. PubMed ID: 23138261
[TBL] [Abstract][Full Text] [Related]
19. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
20. New Concepts in Dopamine D
Urs NM; Peterson SM; Caron MG
Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]